Profil News

Our expert

Dr. Lars Bochmann

Director Scientific Communication

January 29, 2019

Digital Diabetes: better trials, better drugs, better care

Background Diabetes is a multidimensional challenge for global societies. Despite the availability of drugs and technology many patients don’t reach their treatment goals. According to the UK

January 15, 2019

Glucose-Infusion-Rate based categorization of glucose clamps

The glucose clamp is a method for the determination of pharmacokinetic and pharmacodynamic (PK/PD) effects of anti-diabetic drugs (e.g. insulin) where the blood glucose (BG) concentration lowering

January 8, 2019

Update on Brexit: Impact on future and current clinical trials in Germany

As the withdrawal of the United Kingdom from the European Union is coming closer, the Competent Authority in Germany (BfArM) recently published their procedures for the period thereafter. Please find

January 3, 2019

Happy new year 2019

2018 is over - and the Profil blog has seen many interesting articles through the last months. We have posted about conferences, webinars and scientific topics for clinical diabetes researchers. We

December 19, 2018

Pramlintide as adjunct therapy for the treatment of type 1 diabetes

Where are we today? Insulin treatment for type 1 diabetes mellitus (T1D) has improved over the past decades due to advances in insulin formulations and administration techniques. Nevertheless,

December 11, 2018

Obesity treatment with lorcaserin

New data on metabolic & cardiovascular safety and efficacy Worldwide, the incidence of obesity is increasing dramatically having almost tripled in the last 40 years [1]. In 2016, 39% of adults aged

December 4, 2018

New data on cardiovascular outcomes with dapagliflozin

Putting effects of SGLT2 inhibitors into perspective The DECLARE-TIMI 58 trial [1] investigated the effects of treatment with dapagliflozin on cardiovascular outcomes in people with type 2 diabetes

November 28, 2018

Glucose-Responsive Insulin

The first idea [1] for a glucose-responsive insulin (GRI, commonly referred to as smart insulin) was pitched almost 40 years ago, but to our knowledge only one compound has since undergone clinical

November 13, 2018

New strategies for the treatment of obesity and metabolic dysfunctions

Targeting the incretin/glucagon system with agonists Figure 1: Schematic representation of the effects of multi-agonists targeting the receptors for GLP-1/Glucagon, GLP-1/GIP and

Profil Germany News

See what’s new at Profil